Hepatobiliary manifestations of COVID-19 and their impact on severity and outcomes in a single center in Saudi Arabia

• DOI: 10.25122/jml-2022-0047
• Publication Date: 2022-11-19T07:50:12Z
• Authors: Reem Al Argan; ; ; Mona Ismail; ; Dania AlKhafaji; ; Raed Alsulaiman; ; Fatimah Ismaeel; ; Reem AlSulaiman; ; Lameyaa Alsheekh; ; Tariq Alsaif; ; Feras Alkuwaiti; ; Abir Al Said; ; Safi Alqatari; ; Abrar Alwaheed; ; Alaa Alzaki; ; Marwan Al Wazzeh; ; Abdulaziz AlQuorain
• Keywords: 2019-20 coronavirus outbreak; Single Center; Betacoronavirus; Center (category theory)

Recognizing hepatic manifestations of COVID-19 and their impact on the severity outcome is crucial in managing this emerging pandemic. However, we lack such reported data Saudi Arabia regarding clinical entity. This a retrospective observational study conducted 387 patients with disease who were hospitalized at King Fahad Hospital University from March-September 2020. The total cohort was divided into two groups: liver non-liver involvement. Then, frequency determined, followed by comparing among groups. A included, which 72.87% had manifestations. most prevalent abnormalities high LDH 308 (79.58%) AST 205 (52.97%), GGTP 124 (31.26%), ALT 74 (19.12%), PT/INR 66 (17.05%), direct bilirubin 51 (12.40%), 46 (11.88%), low albumin 48 (12.4%). Univariate analyses showed that involvement significantly associated severe (31.91%) critical (34.75%) presentation (P<0.001). Multivariate regression analysis presence an independent risk factor for or (OR 2.44; P<0.001), longer hospitalization 2.27; P=0.001), ICU admission P=0.006). current common setting disease. Such higher worse outcome.